<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04735679</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL21_0053</org_study_id>
    <nct_id>NCT04735679</nct_id>
  </id_info>
  <brief_title>Characterization of Pulmonary Microbiome in Cystic Fibrosis Patients</brief_title>
  <acronym>SPutOM-CF</acronym>
  <official_title>Multi-omic Longitudinal Characterization of Pulmonary Microbiome in Cystic Fibrosis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The composition and role of the pulmonary microbiota is not yet well described in cystic&#xD;
      fibrosis patients.&#xD;
&#xD;
      The objective of our longitudinal follow-up of primary colonised patients is to show the&#xD;
      presence of a link between the composition of the microbiota and the effectiveness of&#xD;
      antibiotic therapy.&#xD;
&#xD;
      All patients followed at the Montpellier CF center will be asked to participate in this&#xD;
      cohort. All patients have a regular follow-up every 1 to 6 months and will be asked at each&#xD;
      visit to keep their sputum sample in excess of the analyses requested for their follow-up&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The composition and role of the pulmonary microbiota is not yet well described in cystic&#xD;
      fibrosis patients.&#xD;
&#xD;
      According to our hypothesis, the lung microbiota shapes the lung environment of cystic&#xD;
      fibrosis patients and modifies the effectiveness of antibiotic treatments and the course of&#xD;
      the disease. The objective of our longitudinal follow-up of primary colonised patients is to&#xD;
      show the presence of a link between the composition of the microbiota and the effectiveness&#xD;
      of antibiotic therapy. Finally, the management of first colonisations could justify the&#xD;
      characterisation of the microbiota in order to develop innovative diagnostic tests for the&#xD;
      follow-up of patients suffering from cystic fibrosis and possibly the identification of new&#xD;
      therapeutic agents based on the microbiota.&#xD;
&#xD;
      All patients followed at the Montpellier CF centre will be asked to participate in this&#xD;
      cohort. All patients have a regular follow-up every 1 to 6 months and will be asked at each&#xD;
      visit to keep their sputum sample in excess of the analyses requested for their follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>to determine a characterisation of the microorganisms of the lung microbiota</measure>
    <time_frame>1 day</time_frame>
    <description>to characterise the microorganisms of the lung microbiota and their interspecific interactions by taxonomic and functional analyses.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>to determine a ink between the Composition of the microbiota</measure>
    <time_frame>1 day</time_frame>
    <description>To demonstrate the relationship between the composition of the microbiota and the evolution of the disease Defines the effectiveness of anti-inflammatory biotherapy in patients with cystic fibrosis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>to determine a Effectiveness of antibiotic therapy</measure>
    <time_frame>1 day</time_frame>
    <description>To identify abiotic conditions that may contribute to the gap between the efficacy of antibiotics in vitro and in vivo.&#xD;
Show that the microbiota plays a role in the effectiveness of antibiotic treatment.</description>
  </primary_outcome>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Cystic Fibrosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Cystic fibrosis patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
        - Cystic fibrosis patient&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
        - Refusal to participate in this research&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raphael CHIRON, PU-PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals of Montpellier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Raphael CHIRON, PU-PH</last_name>
    <phone>467336089</phone>
    <phone_ext>33</phone_ext>
    <email>r-chiron@chu-montpellier.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexandre COUDRAT</last_name>
    <email>alexandre.coudrat@outlook.frfr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Uh Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>RAPHAEL CHIRON, PU-PH</last_name>
      <phone>467336089</phone>
      <phone_ext>33</phone_ext>
      <email>r-chiron@chu-montpellier.fr</email>
    </contact>
    <contact_backup>
      <last_name>Alexandre Coudrat</last_name>
      <phone>467335937</phone>
      <phone_ext>33</phone_ext>
      <email>alexandre-coudrat@outlook.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 29, 2021</study_first_submitted>
  <study_first_submitted_qc>January 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 3, 2021</study_first_posted>
  <last_update_submitted>February 2, 2021</last_update_submitted>
  <last_update_submitted_qc>February 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MICROBIOLOGY</keyword>
  <keyword>MULTI-OMIC</keyword>
  <keyword>SPUTUM</keyword>
  <keyword>PULMONARY MICROBIOTA</keyword>
  <keyword>CYSTIC FIBROSIS</keyword>
  <keyword>COHORT</keyword>
  <keyword>ANTIBIOTHERAPY</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>NC</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

